Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q1- Text added to 2022 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
accretion, addressing, Advantage, aide, ALLOCYTE, Allograft, Amniotic, AMPLIFY, assay, assessing, assessment, automated, BiFORM, Bioactive, biochemical, biomarker, ceased, Cellular, collagen, component, criteria, decision, diagnostic, dictate, Distinguishing, dual, efficacy, EMR, enable, finite, fixed, Holdback, hydrolyzed, imager, indemnification, Indemnity, Inductive, Kingdom, Matrix, Medicare, membership, Membrane, mobile, Moldable, monetary, multispectral, negotiated, noncash, nonmarketable, nonoperating, organized, orthobiologic, oxygen, pad, partly, predominantly, pressure, protocol, prove, quantify, recommended, regenerative, registered, removal, Ryan, Scendia, segment, slightly, smart, solution, synergistically, TEXAGEN, therapy, trajectory, unaffiliated, Verified, withheld
Removed:
advertising, ASU, beneficially, collect, formulary, large, launch, lead, overstated, uncollectible, unrelated
Valuein 2022 Q1 filing- Value in 2022 Q2 filing
Original filings
Filing view